Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders
ReportsWeb.com has announced the addition of the “Global Rx-to-OTC Switching Market”, The report classifies the global Rx-to-OTC Switching Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restra
(EMAILWIRE.COM, March 23, 2018 ) Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders
Summary
Rx-to-OTC switching is the process in which a drug which has formerly been marketed as a prescription-only Rx drug is authorized for sale to the general public, without the need for a prescription. For patients and healthcare providers, OTC products can reduce the cost of medical treatment and allow easier access of drugs to patients, and for pharmaceutical companies, they allow lifecycle extension of an off-patent drug by transferring it to the consumer environment, and facilitate renewed revenue growth.
FREE | Request Sample Copy is Available at http://www.reportsweb.com/inquiry&RW00011251999/sample
Based on overall revenue, the OTC pharmaceutical market has been dominated by four main categories: cough, cold, and allergy; analgesics; dermatologicals; and gastrointestinals. These categories have led the OTC drugs market over the last two decades in revenue and volume.
GBI Research conducted a targeted industry survey of experts and key opinion leaders (KOL) in the field of Rx-to-OTC switching to gather insight and opinions on the trends and commercial prospects of switching pharmaceuticals. The majority of these respondents believe that there will be an increase in Rx-to-OTC switching in the next five years, particularly in the weight control, dermatological and cough, cold and allergy segments.
Key barriers to switching include the potential for misuse and abuse of drugs, particularly for analgesics, and the resultant need to demonstrate safety and clear labelling to regulatory agencies. A lack of harmonization in OTC approval processes between different countries also increases the burden for companies that want to launch their products across multiple territories.
Browse complete Report@ http://www.reportsweb.com/Current-and-Future-Trends-in-Rx-to-OTC-Switching-with-Insight-from-Key-Industry-Opinion-Leaders
Reasons to buy
-Understand the current status of the field of therapeutic Rx-to-OTC Switching, and the relative clinical and commercial success of currently marketed products.
-Assess the pipeline for Rx-to-OTC Switching split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, central nervous system disorders, ophthalmology, and genetic disorders.
-Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline.
-Understand the level of involvement in the landscape on the part of big pharma companies, and the extent to how Rx-to-OTC Switching fit into the overall portfolios of companies in this field.
-Understand the strategic consolidations landscape in Rx-to-OTC Switching across the past decade
Else place an Inquire before Purchase “Global Coronary Stents Market Size, Status and Forecast 2022” @ http://www.reportsweb.com/inquiry&RW00011251999/buying
(Note: If you have any special requirements, please let us know and we will offer you the report as you want.)
Contact Info:
Name: Sameer Joshi
Organization: ReportsWeb
Email: sales@reportsweb.com
Phone: +1-646-491-9876
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Summary
Rx-to-OTC switching is the process in which a drug which has formerly been marketed as a prescription-only Rx drug is authorized for sale to the general public, without the need for a prescription. For patients and healthcare providers, OTC products can reduce the cost of medical treatment and allow easier access of drugs to patients, and for pharmaceutical companies, they allow lifecycle extension of an off-patent drug by transferring it to the consumer environment, and facilitate renewed revenue growth.
FREE | Request Sample Copy is Available at http://www.reportsweb.com/inquiry&RW00011251999/sample
Based on overall revenue, the OTC pharmaceutical market has been dominated by four main categories: cough, cold, and allergy; analgesics; dermatologicals; and gastrointestinals. These categories have led the OTC drugs market over the last two decades in revenue and volume.
GBI Research conducted a targeted industry survey of experts and key opinion leaders (KOL) in the field of Rx-to-OTC switching to gather insight and opinions on the trends and commercial prospects of switching pharmaceuticals. The majority of these respondents believe that there will be an increase in Rx-to-OTC switching in the next five years, particularly in the weight control, dermatological and cough, cold and allergy segments.
Key barriers to switching include the potential for misuse and abuse of drugs, particularly for analgesics, and the resultant need to demonstrate safety and clear labelling to regulatory agencies. A lack of harmonization in OTC approval processes between different countries also increases the burden for companies that want to launch their products across multiple territories.
Browse complete Report@ http://www.reportsweb.com/Current-and-Future-Trends-in-Rx-to-OTC-Switching-with-Insight-from-Key-Industry-Opinion-Leaders
Reasons to buy
-Understand the current status of the field of therapeutic Rx-to-OTC Switching, and the relative clinical and commercial success of currently marketed products.
-Assess the pipeline for Rx-to-OTC Switching split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, central nervous system disorders, ophthalmology, and genetic disorders.
-Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline.
-Understand the level of involvement in the landscape on the part of big pharma companies, and the extent to how Rx-to-OTC Switching fit into the overall portfolios of companies in this field.
-Understand the strategic consolidations landscape in Rx-to-OTC Switching across the past decade
Else place an Inquire before Purchase “Global Coronary Stents Market Size, Status and Forecast 2022” @ http://www.reportsweb.com/inquiry&RW00011251999/buying
(Note: If you have any special requirements, please let us know and we will offer you the report as you want.)
Contact Info:
Name: Sameer Joshi
Organization: ReportsWeb
Email: sales@reportsweb.com
Phone: +1-646-491-9876
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results